A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors

References

• Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, . Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated on human liver and cancer tissue. Eur J Cancer. 1998; 34:1274–81.
   PubMed Web of Science ®Google Scholar
• Igbal S, Lenz HJ. Capecitabine: The new generation of fluoropyrimides in colorectal cancer. Expert Rev Anticancer Ther. 2004; 4:947–55.
   PubMedGoogle Scholar
• Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003; 63:217–36.
   PubMed Web of Science ®Google Scholar
• Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer. Anticancer Drugs. 2009; 20:217–29.
   PubMed Web of Science ®Google Scholar
• Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, . Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998; 16:2977–85.
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin. Mechanism of action and antineoplastic activity. Semin Oncol. 1998; 25Suppl 5:4–12.
   PubMedGoogle Scholar
• Simpson D, Dunn C, Curran M, Goa KL. Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. 2003; 63:2127–56.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: Prospects and directions. Semin Oncol. 2002; 295 Suppl 15: 34–9.
   PubMedGoogle Scholar
• Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, . A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer. 2009; 100:1720–4.
   PubMed Web of Science ®Google Scholar
• Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998; 25Suppl 5:13–22.
   PubMedGoogle Scholar
• Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990; 25:299–303.
   PubMed Web of Science ®Google Scholar
• Pronk L, Vasey PA, Sparreboom A, Reigner B, Planting AS, Gordon RJ, . A phase I and pharmacokinetic study of the concentration of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer. 2000; 83:22–9.
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4:1013–9.
   PubMed Web of Science ®Google Scholar
• Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2004; 90:1329–33.
   PubMed Web of Science ®Google Scholar
• Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, . A phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung carcinoma. Cancer. 2003; 98:1918–24.
   PubMedGoogle Scholar
• O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, . Superior survival with docetaxel plus capecitabine combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002; 20:2812–23.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, . XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22:2084–91.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek G, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, . Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003; 21:1307–12.
   PubMed Web of Science ®Google Scholar
• Zeuli M, Constanzo ED, Sdrobolini A, Gasperoni S, Paoloni FP, Capri A, . Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study. Ann Oncol. 2001; 12:1737–41.
   PubMedGoogle Scholar
• Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006; 12:131–41.
   PubMedGoogle Scholar
• Nagore E, Insa A, Sanmartin O. Antineoplastic therapy – induced palmar plantar erythrodysesthesia. Incidence, recognition and management. Am J Clin Dermatol. 2000; 1:225–34.
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92:205–16.
   PubMed Web of Science ®Google Scholar
• Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, . Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001; 19:1096–104.
   PubMed Web of Science ®Google Scholar
• Janinis J, Papadakou M, Xidakis E, Boukis H, Poulis A, Panagos G, . Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: A phase II feasibility study. Am J Clin Oncol. 2000; 23:128–31.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Costenla M, Boni C, . Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol. 2007; 25:3188–90.
   PubMedGoogle Scholar
• Estevez LG, Sanchez Rovira P, Domine M, Leon A, Calvo I, Jaen A, . Biweekly docetaxel and capecitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: Preliminary results of a phase II and pharmacogenomic study. Semin Oncol. 2004; 31Suppl 5:31–6.
   PubMedGoogle Scholar